TABLE 2.
Activities of compounds in combination with other anti-HIV agents
| Agent used in combination (mechanism of action)a | Synergy vol (μM2% [SD])b
|
||
|---|---|---|---|
| Calanolide A | Costatolide | Dihydrocostatolide | |
| Resobene (AFI) | 12 (2) | 10 (1) | 4 (2) |
| AZT (NRTI) | 136 (15) | 223 (29) | 111 (8) |
| ddI (NRTI) | 95 (10) | 152 (12) | 37 (6) |
| ddC (NRTI) | 74 (7) | 525 (49) | 67 (8) |
| 3TC (NRTI) | 129 (18) | 156 (29) | 25 (3) |
| d4T (NRTI) | 115 (5) | 185 (9) | 58 (3) |
| UC10 (NNRTI) | 12 (3) | 30 (2) | 50 (9) |
| UC781 (NNRTI) | 123 (10) | 152 (12) | 143 (12) |
| Ritonavir (PI) | 112 (8) | 182 (15) | NDc |
| Indinavir (PI) | 12 (1) | 20 (1) | ND |
| Nelfinavir (PI) | 49 (5) | 15 (10) | ND |
| Saquinavir (PI) | 95 (15) | 120 (12) | ND |
a
Abbreviations for mechanism of action: NRTI, nucleoside RT inhibitor; NNRTI, nonnucleoside RT inhibitor; PI, protease inhibitor; AFI, attachment-fusion inhibitor.
b
Mean synergy volume was calculated from two replicate anti-HIV assays with drug combinations. Synergy volumes were calculated by the Prichard and Shipman (28) MacSynergy II program at the 95% confidence interval.
c
ND, not determined.